evusheld
astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.
saphnelo
astrazeneca ab - anifrolumab - erütematoosne luupus, süsteemne - immunosupressandid - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.
riltrava aerosphere
astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.
tezspire
astrazeneca ab - tezepelumab - astma - ravimid hingamisteede obstruktiivsete haiguste, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastilised ained - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
imfinzi
astrazeneca ab - durvalumab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
bricanyl tablett
astrazeneca uk limited - terbutaliin - tablett - 5mg 100tk; 5mg 60tk
zomig tablett
astrazeneca uk limited - zolmitriptaan - tablett - 2,5mg 3tk
imfinzi süstelahus
astrazeneca uk limited - durvalumab - süstelahus - 50mg 1ml 10ml 3tk
emla kreem
astrazeneca ab - lidokaiin+prilokaiin - kreem - 25mg+25mg 1g 100g 1tk; 25mg+25mg 1g 5g 1tk; 25mg+25mg 1g 30g 1tk; 25mg+25mg 1g 5g 5tk